Recent Updates
Recently added Catalysts
TSHA Positive Sentiment Score: 65/100

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

Thursday, May 4, 2023 1 min read
Key Takeaway: Taysha Gene Therapies, a clinical-stage gene therapy company, announced it will release its financial results for the first quarter of 2023 on May 11. Alongside the results, the company will host a conference call and webcast to provide a corporate update. With a focus on developing gene therapies for monogenic diseases of the central nervous system, Taysha aims to improve patient outcomes through its innovative treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Taysha Gene Therapies is advancing in gene therapy for CNS diseases.
  • The upcoming financial results may indicate growth and progress.
  • The company has a strong collaboration with UT Southwestern Gene Therapy Program.

Full Press Release Details

DALLAS, May 04, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2023, and host a corporate update conference call and webcast on Thursday, May 11, 2023, at 4:30 PM Eastern Time.
Conference Call Details
Thursday, May 11, at 4:30 PM Eastern Time / 3:30 PM Central Time
Toll Free: 855-327-6837
International: 631-891-4304
Conference ID: 10021767
https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Director, Head of Corporate Communications
Taysha Gene Therapies
hcollins@tayshagtx.com
Canale Communications
carolyn.hawley@canalecomm.com

Frequently Asked Questions

When will Taysha report its financial results?

Taysha will report its financial results on May 11, 2023, at 4:30 PM ET.

How can I join Taysha's conference call?

You can join by calling 855-327-6837 (toll-free) or 631-891-4304 (international).

What is Taysha Gene Therapies' focus?

Taysha focuses on developing AAV-based gene therapies for monogenic CNS diseases.

Where can I find more information about Taysha?

More information is available on Taysha's website at www.tayshagtx.com.

What is the mission of Taysha Gene Therapies?

Taysha aims to eradicate monogenic CNS diseases and develop curative medicines.

Tags: TSHA Viatris Investor Conferences Healthcare Taysha Gene Therapies CNS disease gene therapy financial results
Last updated: May 4, 2023